Terumo BCT and Marker Therapeutics received the first device FDA Emergency Use Authorization (EUA) to treat acute respiratory failure in COVID-19 patients
Terumo Blood and Cell Technologies - Terumo BCT
Tıbbi Cihazlar – BMT Medikal
TERUMO – Özgün Kimya
Mehmet Ozdemir - Finance and Administration Manager - Terumo Blood and Cell Technologies | LinkedIn